All In MedTech

FDA Clearance Tracker · P210007-S002

Vivistim® System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Mar 25, 2024 (this decision)Source: openFDAMethods & limitations

PMA supplement

The decision

FDA number
P210007-S002
Device name
Vivistim® System
Applicant location
Austin, TX
Received
Jan 23, 2024
Decided
Mar 25, 2024
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P210007

Device type

Device class
Class III

Every decision under product code QPY

FDA's approval statement

As written in FDA's record.

The Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) has completed its review of your premarket approval application (PMA) 180-day supplement, which requested approval for modifications to device labeling. Based upon the information submitted, the PMA supplement is approved.

Source documents

Other decisions for Mobia Medical, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.